Astrazeneca Phar

{
  "main_header": {
    "sid": 777011,
    "name": "Astrazeneca Phar",
    "stock_name": "Astrazeneca Phar",
    "full_name": "Astrazeneca Pharma India Ltd",
    "name_url": "stocks-analysis/astrazeneca-phar",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "8,415.00",
    "chg": 139,
    "chgp": "1.68%",
    "dir": 1,
    "prev_price": "8,276.00",
    "mcapval": "20,894.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506820,
    "symbol": "ASTRAZEN",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE203A01020",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "5.71 k",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astrazeneca-phar-777011-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-3906060",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstrazenecaPhar_mojoScore_3906060.png",
        "date": "2026-03-23 10:10:02",
        "description": "Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Astrazeneca Pharma India Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrazeneca-pharma-india-ltd-faces-bearish-momentum-amid-technical-downgrade-3892727",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstrazenecaPhar_technicaldot_3892727.png",
        "date": "2026-03-16 08:02:00",
        "description": "Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests caution for investors amid a challenging market backdrop."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-3886659",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstrazenecaPhar_mojoScore_3886659.png",
        "date": "2026-03-12 10:10:34",
        "description": "Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-3863039",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AstrazenecaPhar_mojoScore_3863039.png",
        "date": "2026-03-01 10:10:24",
        "description": "Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-3845534",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstrazenecaPhar_mojoScore_3845534.png",
        "date": "2026-02-18 10:10:47",
        "description": "Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Are Astrazeneca Pharma India Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-astrazeneca-pharma-india-ltd-latest-results-good-or-bad-3835738",
        "imagepath": "",
        "date": "2026-02-12 19:49:14",
        "description": "AstraZeneca Pharma India Ltd's latest financial results for Q3 FY26 reveal a complex picture of growth and operational challenges. The company reported net sales of ₹611.57 crores, reflecting a sequential growth of 9.39% from the previous quarter and a substantial year-on-year increase of 38.90%. This marks the seventh consecutive quarter of revenue growth, indicating strong demand across its therapeutic portfolio, which includes oncology, cardiovascular, respiratory, and diabetes segments.\n\nHowever, the profitability metrics present a contrasting scenario. The net profit for the quarter was ₹32.59 crores, which represents a significant sequential decline of 39.89%. This decline in profit occurred despite the robust revenue growth and raises concerns regarding cost management and operational efficiency. The operating profit before depreciation, interest, and tax (PBDIT) fell to ₹44.83 crores, down 40.38% fr..."
      },
      {
        "title": "AstraZeneca Pharma Q3 FY26: Margin Pressure Dampens Strong Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/astrazeneca-pharma-q3-fy26-margin-pressure-dampens-strong-revenue-growth-3835193",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstrazenecaPhar_quaterlyResult_3835193.png",
        "date": "2026-02-12 09:47:05",
        "description": "AstraZeneca Pharma India Ltd. delivered a mixed performance in Q3 FY26 (Oct-Dec'25), with robust revenue growth overshadowed by significant margin compression and profit decline. The pharmaceutical major reported net profit of ₹32.59 crores, down 39.89% quarter-on-quarter from ₹54.22 crores in Q2 FY26, though up 5.64% year-on-year from ₹30.85 crores in Q3 FY25. The stock has declined 4.13% following the results announcement, trading at ₹8,696.15 and reflecting investor concerns about operational efficiency despite strong topline momentum."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-3825669",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstrazenecaPhar_mojoScore_3825669.png",
        "date": "2026-02-07 10:10:48",
        "description": "Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Astrazeneca Pharma India Ltd Sees Technical Momentum Shift Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrazeneca-pharma-india-ltd-sees-technical-momentum-shift-amid-mixed-signals-3815480",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AstrazenecaPhar_technicaldot_3815480.png",
        "date": "2026-02-02 08:04:04",
        "description": "Astrazeneca Pharma India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a modest day gain of 0.97%, the stock’s technical indicators present a complex picture, with some signals suggesting caution while others hint at potential stabilisation. This article analyses the recent technical parameter changes, key momentum indicators, and how Astrazeneca’s performance compares with broader market benchmarks."
      }
    ],
    "total": 354,
    "sid": "777011",
    "stock_news_url": "https://www.marketsmojo.com/news/astrazeneca-pharma-india-777011"
  },
  "announcements": [
    {
      "details": "AstraZeneca Pharma India Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "AstraZeneca Pharma India Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "05-Dec-2019"
    },
    {
      "details": "AstraZeneca Pharma India Limited has informed the Exchange a copy of disclosure of Related Party Transactions for half year ended September 30, 2019 under Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended",
      "source": "NSE",
      "caption": "AstraZeneca Pharma India Limited - Other General Purpose",
      "datetime": "27-Nov-2019"
    },
    {
      "details": "AstraZeneca Pharma India Limited has informed the Exchange regarding 'Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on November 13, 2019 in respect of the Unaudited Financial Results for the quarter ended September 30, 2019 approved in the Board Meeting of the Company held on November 11, 2019. '.",
      "source": "NSE",
      "caption": "AstraZeneca Pharma India Limited - Updates",
      "datetime": "15-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Astrazeneca Pharma India Ltd has declared <strong>1600%</strong> dividend, ex-date: 18 Jul 25",
          "dt": "2025-07-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Astrazeneca Pharma India Ltd has announced <strong>2:10</strong> stock split, ex-date: 15 Jun 06",
          "dt": "2006-06-15",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Astrazeneca Pharma India Ltd is Rated Sell

2026-03-23 10:10:02

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO. This rating was last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 23 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Astrazeneca Pharma India Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-03-16 08:02:00

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests caution for investors amid a challenging market backdrop.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-03-12 10:10:34

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-03-01 10:10:24

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-02-18 10:10:47

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Are Astrazeneca Pharma India Ltd latest results good or bad?

2026-02-12 19:49:14

AstraZeneca Pharma India Ltd's latest financial results for Q3 FY26 reveal a complex picture of growth and operational challenges. The company reported net sales of ₹611.57 crores, reflecting a sequential growth of 9.39% from the previous quarter and a substantial year-on-year increase of 38.90%. This marks the seventh consecutive quarter of revenue growth, indicating strong demand across its therapeutic portfolio, which includes oncology, cardiovascular, respiratory, and diabetes segments. However, the profitability metrics present a contrasting scenario. The net profit for the quarter was ₹32.59 crores, which represents a significant sequential decline of 39.89%. This decline in profit occurred despite the robust revenue growth and raises concerns regarding cost management and operational efficiency. The operating profit before depreciation, interest, and tax (PBDIT) fell to ₹44.83 crores, down 40.38% fr...

Read full news article

AstraZeneca Pharma Q3 FY26: Margin Pressure Dampens Strong Revenue Growth

2026-02-12 09:47:05

AstraZeneca Pharma India Ltd. delivered a mixed performance in Q3 FY26 (Oct-Dec'25), with robust revenue growth overshadowed by significant margin compression and profit decline. The pharmaceutical major reported net profit of ₹32.59 crores, down 39.89% quarter-on-quarter from ₹54.22 crores in Q2 FY26, though up 5.64% year-on-year from ₹30.85 crores in Q3 FY25. The stock has declined 4.13% following the results announcement, trading at ₹8,696.15 and reflecting investor concerns about operational efficiency despite strong topline momentum.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-02-07 10:10:48

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Astrazeneca Pharma India Ltd Sees Technical Momentum Shift Amid Mixed Signals

2026-02-02 08:04:04

Astrazeneca Pharma India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a modest day gain of 0.97%, the stock’s technical indicators present a complex picture, with some signals suggesting caution while others hint at potential stabilisation. This article analyses the recent technical parameter changes, key momentum indicators, and how Astrazeneca’s performance compares with broader market benchmarks.

Read full news article

View All News